Joshua Jackson joined Ropes & Gray in 2008 and is a member of the firm's technology transactions and life sciences practice groups. Josh advises public and private companies, investors, and universities in a variety of transactions where technology or IP assets are the fundamental drivers. These transactions include intellectual property licensing and transfer, product development and research collaborations, joint ventures, technology-focused mergers and acquisitions, cloud contracts, branding, supply agreements, copyright and trademark matters, venture financings and other strategic relationships. Josh works with companies in a broad range of industries including biotechnology, pharmaceutical, medical device, semiconductor, cloud-computing, software, financial technology, digital health, sports, and media and entertainment industries. Josh also advises companies in connection with privacy and data security matters, including evaluating data privacy policies and practices, developing social media best practices and complying with data privacy laws and regulations.
In addition to his transactional experience, Josh has extensive experience assisting clients ranging from small start-up companies to large domestic and international corporations with preparing and prosecuting patent applications, strategically developing and managing patent portfolios, forming IP ownership and monetization strategies, and conducting patent infringement, validity and freedom to operate analyses for a wide range of technologies.
Prior to joining the firm, Josh's graduate work at the University of Michigan focused on research topics in the area of implantable MEMS neural probes and in exploiting the near-infrared absorbance properties of carbon nanotubes for destroying cancerous cells. Josh has also worked at Cleveland Clinic where he researched the effects of Deep Brain Stimulation on Parkinson's disease.
- Represented Homology Medicines in its research and development collaboration with Novartis to use Homology’s gene editing technology to develop new treatments for select ophthalmic targets and hemoglobin blood disease.